A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation

BACKGROUND The sodium-glucose cotransporter 2 inhibitor, dapagliflozin, has been shown to improve diabetic control and reduce blood pressure in patients with type 2 diabetes mellitus. Its effects on micro- and macrovascular structure and function have not yet been reported. METHODS This was a prospective, single-centre, placebo-controlled, double-blind… CONTINUE READING